Please login to the form below

Not currently logged in
Email:
Password:

Aricept patch filed with FDA

The US FDA has accepted for review a New Drug Application for a patch version of Eisai's blockbuster Alzheimer's disease drug Aricept

The US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for a patch version of Eisai's blockbuster Alzheimer's disease drug Aricept (donepezil).

The filing comes as the oral formulation of the drug is facing patent expiry.  Eisai said earlier this year that it expects annual US sales of Aricept to plummet from $2bn to $800m by 2013 because of the introduction of generic competition.

The transdermal product, which is expected to improve patient compliance, will be co-promoted by Eisai and Pfizer if it is approved in the US. Pfizer already co-promotes the oral version of the drug in the US.

The weekly patch was developed through a partnership between Eisai and Teikoku Pharma USA, a subsidiary of Japan's Teikoku Seiyaku that specialises in developing transdermal formulation of medicines.

The NDA, which was submitted on June 30, seeks approval of the patch for mild, moderate and severe stages of Alzheimer's disease. The oral formulation of Aricept, which is sold as regular tablets and disintegrating tablets, must be taken every day. It is the only drug currently approved by the FDA for all three stages of the disease.

Earlier this year, the FDA approved a high-dose, 23mg formulation of the oral drug, which was previously available only in 5mg and 10mg tablets. The high-dose product has three years of marketing exclusivity.

If the patch version of the drug is cleared for marketing, it will compete with Novartis' Exelon Patch, which is approved for mild to moderate Alzheimer's disease, as well as mild to moderate Parkinson's disease dementia. The Novartis patch was cleared by the FDA in 2007 as the first transdermal drug for Alzheimer's disease.

20th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics